CSTLNasdaqServices-Medical LaboratoriesFiscal year ends December 31
CASTLE BIOSCIENCES INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$32.16+0.20 (+0.64%)
Close on Oct 19, 2026
- Market cap
- $977.78M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Castle Biosciences statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Services-Medical Laboratories companies for comparison
Valuation
| Measure | Castle Biosciences | Industry median |
|---|---|---|
| Market Cap | $982.63M | $1.11B |
| Enterprise Value | $725.90M | $1.41B |
| PS Ratio | 2.75 | 1.60 |
| PB Ratio | 2.09 | 3.03 |
| P/TBV Ratio | 2.62 | 4.99 |
| P/OCF Ratio | 23.05 | 15.44 |
Enterprise value
| Measure | Castle Biosciences | Industry median |
|---|---|---|
| EV / Sales | 2.03 | 1.69 |
Income (trailing twelve months)
| Measure | Castle Biosciences | Industry median |
|---|---|---|
| Revenue | $357.28M | $561.90M |
| Gross Profit | $276.03M | $173.32M |
| Operating Income | -$32.11M | -$1.81M |
| Net Income | -$19.42M | -$1.16M |
| EBITDA | -$16.52M | -$20.72K |
| EPS (Diluted) | -$0.66 | -$0.02 |
Margins
| Measure | Castle Biosciences | Industry median |
|---|---|---|
| Gross Margin | 77.3% | 33.1% |
| Operating Margin | -8.99% | -4.45% |
| Profit Margin | -5.43% | -2.91% |
| EBITDA Margin | -4.62% | 2.41% |
| FCF Margin | -0.14% | 3.13% |
Returns
| Measure | Castle Biosciences | Industry median |
|---|---|---|
| Return on Equity (ROE) | -4.20% | 1.84% |
| Return on Assets (ROA) | -3.51% | -3.06% |
| Return on Invested Capital (ROIC) | -12.6% | 2.11% |
| Return on Capital Employed (ROCE) | -6.36% | -0.57% |
Growth
| Measure | Castle Biosciences | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 3.18% | 6.92% |
| FCF Growth (YoY) | -101.4% | -6.04% |
| Revenue Growth (3Y CAGR) | 35.9% | 10.9% |
| Revenue Growth (5Y CAGR) | 40.6% | 13.2% |
Balance sheet
| Measure | Castle Biosciences | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $266.81M | $48.71M |
| Total Debt | $10.08M | $140.00M |
| Net Cash (Debt) | $256.73M | $205.49K |
| Net Cash Per Share | $8.40 | $0.01 |
| Equity (Book Value) | $470.03M | $235.16M |
| Book Value Per Share | $15.39 | $3.48 |
| Tangible Book Value | $374.93M | $703.69K |
| Working Capital | $284.59M | $30.48M |
Financial position
| Measure | Castle Biosciences | Industry median |
|---|---|---|
| Current Ratio | 6.04 | 1.40 |
| Quick Ratio | 5.58 | 1.02 |
| Debt / Equity | 0.02 | 0.66 |
| Interest Coverage | -85.62 | -0.63 |
Cash flow (trailing twelve months)
| Measure | Castle Biosciences | Industry median |
|---|---|---|
| Operating Cash Flow | $42.63M | $3.10M |
| Capital Expenditures | -$43.12M | -$18.62M |
| Free Cash Flow | -$489.00K | $23.73M |
| FCF Per Share | -$0.02 | $0.37 |
Efficiency
| Measure | Castle Biosciences | Industry median |
|---|---|---|
| Asset Turnover | 0.65 | 0.87 |
| Inventory Turnover | 8.58 | 11.67 |
| Revenue Per Employee | $404.62K | $228.48K |
| Profits Per Employee | -$21.99K | -$5.75K |
| Employee Count | 883 | 910 |
Dividends and yields
| Measure | Castle Biosciences | Industry median |
|---|---|---|
| Earnings Yield | -1.98% | -0.59% |
| FCF Yield | -0.05% | 1.74% |
| Dividend Yield | 0.00% | 0.61% |
| Shareholder Yield | 0.00% | 0.65% |
| Dividend Per Share | $0.00 | $1.30 |
| Years of Dividend Growth | 0 | 4 |
Shares
| Measure | Castle Biosciences | Industry median |
|---|---|---|
| Shares Outstanding | 30,549,500 | 58,282,400 |
| Shares Change (YoY) | 0.54% | 2.68% |
| Shares Change (QoQ) | 0.70% | 0.32% |
| Float | 29,927,800 | 33,780,100 |
| Shares Held by Insiders | 2.04% | 16.4% |
| Shares Held by Institutions | 89.5% | 85.9% |
Taxes
| Measure | Castle Biosciences | Industry median |
|---|---|---|
| Income Tax | $212.00K | $697.00K |
Scores
| Measure | Castle Biosciences | Industry median |
|---|---|---|
| Altman Z-Score | 6.92 | 2.05 |
| Piotroski F-Score | 4 | 5 |
| Beneish M-Score | -3.46 | -2.71 |
Calculated by StockData from Castle Biosciences's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.